{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T22:18:52Z","timestamp":1757629132894,"version":"3.44.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40264-025-01566-1","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:00:00Z","timestamp":1753992000000},"page":"1161-1175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies"],"prefix":"10.1007","volume":"48","author":[{"given":"Jos\u00e9 M.","family":"Ord\u00f3\u00f1ez-Mena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha N.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Layton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Clifton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshul","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Mather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"24","key":"1566_CR1","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1001\/jama.2021.7517","volume":"325","author":"I See","year":"2021","unstructured":"See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021;325(24):2448\u201356.","journal-title":"JAMA"},{"issue":"20","key":"1566_CR2","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMc2105869","volume":"384","author":"KL Muir","year":"2021","unstructured":"Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964\u20135.","journal-title":"N Engl J Med"},{"issue":"18","key":"1566_CR3","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","volume":"385","author":"S Pavord","year":"2021","unstructured":"Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021;385(18):1680\u20139.","journal-title":"N Engl J Med"},{"issue":"38","key":"1566_CR4","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1016\/j.vaccine.2022.08.007","volume":"40","author":"MA Laffan","year":"2022","unstructured":"Laffan MA, Rees S, Yadavalli M, Ferstenberg LB, Kumar Shankar N, Medin J, et al. Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: case characteristics and associations. Vaccine. 2022;40(38):5585\u201393.","journal-title":"Vaccine"},{"key":"1566_CR5","unstructured":"European Medicines Agency (EMA). DHPC: COVID-19 Vaccine AstraZeneca: risk of thrombocytopenia and coagulation disorders. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en.pdf. Accessed 9 May 2024."},{"issue":"1","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2214-109X(21)00545-3","volume":"10","author":"K Soboleva","year":"2022","unstructured":"Soboleva K, Shankar NK, Yadavalli M, Ferreira C, Foskett N, Putsepp K, et al. Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination. Lancet Glob Health. 2022;10(1):e33\u20134.","journal-title":"Lancet Glob Health"},{"issue":"10300","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(21)01693-7","volume":"398","author":"P Bhuyan","year":"2021","unstructured":"Bhuyan P, Medin J, da Silva HG, Yadavalli M, Shankar NK, Mullerova H, et al. Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis. Lancet. 2021;398(10300):577\u20138.","journal-title":"Lancet"},{"issue":"22","key":"1566_CR8","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092\u2013101.","journal-title":"N Engl J Med"},{"issue":"22","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","volume":"384","author":"NH Schultz","year":"2021","unstructured":"Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124\u201330.","journal-title":"N Engl J Med"},{"key":"1566_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114","volume":"373","author":"A Pottegard","year":"2021","unstructured":"Pottegard A, Lund LC, Karlstad O, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373: n1114.","journal-title":"BMJ"},{"issue":"1","key":"1566_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S1473-3099(23)00736-3","volume":"24","author":"S de Lusignan","year":"2024","unstructured":"de Lusignan S, Hobbs FR, Sheikh A. Lessons from the English primary care sentinel network\u2019s response to the COVID-19 pandemic. Lancet Infect Dis. 2024;24(1):14\u20136.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1566_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063645","volume":"13","author":"H Mullerova","year":"2023","unstructured":"Mullerova H, Medin J, Arnold M, da Silva HG, Kumar S, Nord M, et al. Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic. BMJ Open. 2023;13(1): e063645.","journal-title":"BMJ Open"},{"issue":"1","key":"1566_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262352","volume":"17","author":"SM Nemetski","year":"2022","unstructured":"Nemetski SM, Ip A, Josephs J, Hellmann M. Clotting events among hospitalized patients infected with COVID-19 in a large multisite cohort in the United States. PLoS ONE. 2022;17(1): e0262352.","journal-title":"PLoS ONE"},{"key":"1566_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1931","volume":"374","author":"J Hippisley-Cox","year":"2021","unstructured":"Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374: n1931.","journal-title":"BMJ"},{"issue":"10","key":"1566_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","volume":"76","author":"BK Tan","year":"2021","unstructured":"Tan BK, Mainbourg S, Friggeri A, Bertoletti L, Douplat M, Dargaud Y, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021;76(10):970\u20139.","journal-title":"Thorax"},{"issue":"1","key":"1566_CR16","doi-asserted-by":"publisher","first-page":"7167","DOI":"10.1038\/s41467-022-34668-w","volume":"13","author":"E Burn","year":"2022","unstructured":"Burn E, Li X, Delmestri A, Jones N, Duarte-Salles T, Reyes C, et al. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. Nat Commun. 2022;13(1):7167.","journal-title":"Nat Commun"},{"issue":"1","key":"1566_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.15572","volume":"20","author":"A Greinacher","year":"2022","unstructured":"Greinacher A, Langer F, Makris M, Pai M, Pavord S, Tran H, Warkentin TE. Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources. J Thromb Haemost. 2022;20(1):149\u201356.","journal-title":"J Thromb Haemost"},{"issue":"10306","key":"1566_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(21)01608-1","volume":"398","author":"RJ Perry","year":"2021","unstructured":"Perry RJ, Tamborska A, Singh B, Craven B, Marigold R, Arthur-Farraj P, et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet. 2021;398(10306):1147\u201356.","journal-title":"Lancet"},{"key":"1566_CR19","unstructured":"European Medicines Agency (EMA). Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant]): Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (other viral vaccines). 2021. https:\/\/www.ema.europa.eu\/en\/documents\/prac-recommendation\/signal-assessment-report-embolic-thrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant_en.pdf. Accessed 9 May 2024."},{"issue":"3","key":"1566_CR20","doi-asserted-by":"publisher","DOI":"10.2196\/19773","volume":"6","author":"S de Lusignan","year":"2020","unstructured":"de Lusignan S, Jones N, Dorward J, Byford R, Liyanage H, Briggs J, et al. The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: protocol to develop extended COVID-19 surveillance and trial platforms. JMIR Public Health Surveill. 2020;6(3): e19773.","journal-title":"JMIR Public Health Surveill"},{"issue":"12","key":"1566_CR21","doi-asserted-by":"publisher","DOI":"10.2196\/39141","volume":"8","author":"M Leston","year":"2022","unstructured":"Leston M, Elson WH, Watson C, Lakhani A, Aspden C, Bankhead CR, et al. Representativeness, vaccination uptake, and COVID-19 clinical outcomes 2020\u20132021 in the UK Oxford-Royal College of General Practitioners Research and Surveillance Network: cohort profile summary. JMIR Public Health Surveill. 2022;8(12): e39141.","journal-title":"JMIR Public Health Surveill"},{"key":"1566_CR22","unstructured":"UK Health Security Agency. COVID-19: the green book, chapter 14a. 2023. https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a. Accessed 25 Jan 2024."},{"key":"1566_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100681","volume":"32","author":"M Joy","year":"2023","unstructured":"Joy M, Agrawal U, Fan X, Robertson C, Anand SN, Ordonez-Mena J, et al. Thrombocytopenic, thromboembolic and haemorrhagic events following second dose with BNT162b2 and ChAdOx1: self-controlled case series analysis of the English national sentinel cohort. Lancet Reg Health Eur. 2023;32: 100681.","journal-title":"Lancet Reg Health Eur."},{"issue":"3","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"2200195","DOI":"10.2807\/1560-7917.ES.2023.28.3.2200195","volume":"28","author":"RS Tsang","year":"2023","unstructured":"Tsang RS, Joy M, Byford R, Robertson C, Anand SN, Hinton W, et al. Adverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study. Euro Surveill. 2023;28(3):2200195.","journal-title":"Euro Surveill"},{"issue":"2","key":"1566_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003927","volume":"19","author":"S Kerr","year":"2022","unstructured":"Kerr S, Joy M, Torabi F, Bedston S, Akbari A, Agrawal U, et al. First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales. PLoS Med. 2022;19(2): e1003927.","journal-title":"PLoS Med"},{"issue":"1","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","volume":"41","author":"C Willame","year":"2023","unstructured":"Willame C, Dodd C, Dur\u00e1n CE, Elbers R, Gini R, Bartolini C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases: an ACCESS cohort study. Vaccine. 2023;41(1):251\u201362.","journal-title":"Vaccine"},{"issue":"5","key":"1566_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/pds.5419","volume":"31","author":"E Burn","year":"2022","unstructured":"Burn E, Li X, Kostka K, Stewart HM, Reich C, Seager S, et al. Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiol Drug Saf. 2022;31(5):495\u2013510.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1566_CR28","doi-asserted-by":"publisher","first-page":"107602962093814","DOI":"10.1177\/1076029620938149","volume":"26","author":"W Miesbach","year":"2020","unstructured":"Miesbach W, Makris M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"1566_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1055\/s-0040-1712156","volume":"46","author":"M Levi","year":"2020","unstructured":"Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy: either, neither, or both. Semin Thromb Hemost. 2020;46(7):781\u20134.","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"1566_CR30","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.jtha.2023.04.039","volume":"21","author":"L Nicolai","year":"2023","unstructured":"Nicolai L, Kaiser R, Stark K. Thromboinflammation in long COVID-the elusive key to postinfection sequelae? J Thromb Haemost. 2023;21(8):2020\u201331.","journal-title":"J Thromb Haemost"},{"key":"1566_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.crimmu.2023.100058","volume":"4","author":"R Martins-Goncalves","year":"2023","unstructured":"Martins-Goncalves R, Hottz ED, Bozza PT. Acute to post-acute COVID-19 thromboinflammation persistence: mechanisms and potential consequences. Curr Res Immunol. 2023;4: 100058.","journal-title":"Curr Res Immunol."},{"key":"1566_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100260","volume":"13","author":"NJ Andrews","year":"2022","unstructured":"Andrews NJ, Stowe J, Ramsay ME, Miller E. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Health Eur. 2022;13: 100260.","journal-title":"Lancet Reg Health Eur."},{"key":"1566_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071594","volume":"379","author":"X Li","year":"2022","unstructured":"Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022;379: e071594.","journal-title":"BMJ"},{"issue":"22","key":"1566_CR34","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","volume":"39","author":"J Custers","year":"2021","unstructured":"Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, et al. Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk\/benefit assessment. Vaccine. 2021;39(22):3081\u2013101.","journal-title":"Vaccine"},{"key":"1566_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100270","volume":"12","author":"T Thiele","year":"2022","unstructured":"Thiele T, Weisser K, Schonborn L, Funk MB, Weber G, Greinacher A, et al. Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. Lancet Reg Health Eur. 2022;12: 100270.","journal-title":"Lancet Reg Health Eur."},{"key":"1566_CR36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.2147\/IJGM.S407683","volume":"16","author":"S Hobbi","year":"2023","unstructured":"Hobbi S, Saunders-Hastings P, Zhou CK, Beers J, Srikrishnan A, Hettinger A, et al. Development and validation of an algorithm for thrombosis with thrombocytopenia syndrome (TTS) at Unusual Sites. Int J Gen Med. 2023;16:2461\u20137.","journal-title":"Int J Gen Med."},{"issue":"37","key":"1566_CR37","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1016\/j.vaccine.2023.07.013","volume":"41","author":"F Struyf","year":"2023","unstructured":"Struyf F, Hardt K, Van Rampelbergh R, Shukarev G, Inamdar A, Ruiz-Guinazu J, et al. Thrombosis with thrombocytopenia syndrome: a database review of clinical trial and post-marketing experience with Ad26.COV2.S. Vaccine. 2023;41(37):5351\u20139.","journal-title":"Vaccine"},{"key":"1566_CR38","unstructured":"Bussel JB, Connors JM, Cines DB, Dunbar CE, Michaelis LC, Kreuziger LB, et al. Thrombosis with thrombocytopenia syndrome (also termed vaccine-induced thrombotic thrombocytopenia). Version 1.6. 2020. https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia. Accessed 25 Jan 2024."},{"issue":"7","key":"1566_CR39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.vaccine.2024.01.045","volume":"42","author":"L Schonborn","year":"2024","unstructured":"Schonborn L, Pavord S, Chen VMY, Pai M, Gwarzo DH, Buttery J, et al. Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2024;42(7):1799\u2013811.","journal-title":"Vaccine"},{"key":"1566_CR40","unstructured":"Brighton Collaboration. Updated Brighton Collaboration case definition for thrombosis with thrombocytopenia syndrome (TTS). 2021. https:\/\/brightoncollaboration.us\/wp-content\/uploads\/2023\/08\/TTS-Updated-Brighton-Collaboration-Case-Defintion-Draft-Nov-11-2021.pdf. Accessed 9 May 2024."},{"issue":"1","key":"1566_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/bjh.17705","volume":"195","author":"CN Bagot","year":"2021","unstructured":"Bagot CN. Rapidly established guidelines for the diagnosis and management of vaccine-induced thrombocytopenia and thrombosis (VITT): a double-edged sword? Br J Haematol. 2021;195(1):9\u201310.","journal-title":"Br J Haematol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01566-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T13:52:07Z","timestamp":1757512327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01566-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01566-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"type":"print","value":"0114-5916"},{"type":"electronic","value":"1179-1942"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"18 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"DL: during the conduct of this study, DL was an employee of and received a salary from PEPI Consultancy Ltd and funded by AstraZeneca Ltd, Ariello SRO, and Annexon Biosciences Inc. DL is now employed as the Drug Safety Lead at Lane Clark and Peacock (LCP) LLP, UK. DL is an Editorial Board member of Drug Safety. DL was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. DC reports consulting fees from Oxford University Consulting and Bristol Myers Squibb, and grants from UK Research and Innovation, Wellcome Trust, NIHR, Hong Kong ITC, AstraZeneca, and Glaxo Smith Kline (GSK) and patents held by Oxford University Innovation. DC acknowledges funding from the NIHR Oxford Biomedical Research Centre. JMOM, DK, XF, FF, SNA, MJ, and AT have no conflicts of interest that are directly relevant to the content of this article. AA, AL, and LM are employees of AstraZeneca and may own stock\/shares. SdL has received funding from AstraZeneca, Eli Lilly, GSK, Moderna, MSD, Novo Nordisk, Pfizer, Sanofi, Seqirus, and Takeda and been a member of advisory boards for GSK, Moderna, Sanofi, and Seqirus. He has had meeting expenses funded by AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was granted by the Yorkshire & The Humber\u2013Bradford Leeds Research Ethics Committee (REC) on 3 June, 2021 (REC reference: 21\/YH\/0126).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Routinely collected secondary data were used for this study, therefore informed consent was not required. All patients with flags in their medical records to indicate they have opted out of data sharing did not have their data analyzed or retained, in accordance with the UK National Data Guardian consent\/opt-out model (). This research also comes under the COVID-19 COPI Notice for the use of confidential patient information without consent for COVID-19 research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data underlying the findings described in this article may be obtained in accordance with AstraZeneca\u2019s data-sharing policy described at . Data for studies directly listed on Vivli can be requested through Vivli at . Data for studies not listed on Vivli could be requested through Vivli at . The AstraZeneca Vivli member page is also available outlining further details at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All analysis code is stored in the Oxford-Royal College of General Practitioners (RCGP) Clinical Informatics Digital Hub (ORCHID), which is a trusted research environment, and can be provided by the authors upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JMOM contributed to the conceptualization of the project and formal analysis. DK performed data curation. XF performed data curation. FF contributed to the conceptualization of the project, data curation, project administration, and resources. SNA contributed to data curation, project administration, and resources. DL contributed to the conceptualization of the project, formal analysis, methodology, and project administration. SdL, MJ, DC, AT, and AA contributed to the conceptualization of the project and formal analysis. AL contributed to the conceptualization of the project, methodology, and supervision. LM contributed to the conceptualization of the project, formal analysis, and methodology. All authors contributed to the project protocol and statistical analysis plan, discussed the results, and reviewed and commented on the manuscript at all stages of development. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}